SEC Form 4 · accession 0002010019-26-000024
Natera, Inc. · NTRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Solomon Moshkevich
Officer — PRESIDENT, CLINICALDIAGNOSTICS
Period of report
Aug 3, 2026
Accepted (ET)
Aug 5, 2026 · 9:35 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001604821
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 3, 2026 | S | 410 | $267.9893 | D | 132,019 | D | |
| Common StockF2 | Aug 3, 2026 | S | 300 | $259.98 | D | 131,719 | D | |
| Common StockF2,F3 | Aug 3, 2026 | S | 200 | $261.4875 | D | 131,519 | D | |
| Common StockF2,F4 | Aug 3, 2026 | S | 947 | $263.9415 | D | 130,572 | D | |
| Common StockF2,F5 | Aug 3, 2026 | S | 192 | $265.275 | D | 130,380 | D | |
| Common StockF2,F6 | Aug 3, 2026 | S | 1,233 | $267.7869 | D | 129,147 | D | |
| Common StockF2,F7 | Aug 3, 2026 | S | 128 | $268.6964 | D | 129,019 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.
- F2The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.
- F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.1500 to $261.8250 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.6550 to $264.2400 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.27 to $265.28 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.1550 to $268.1150 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F7The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $268.63 to $268.73 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.